Natarajan P, Kathiresan S. PCSK9 Inhibitors. Cell. 2016;165(5):1037. doi:10.1016/j.cell.2016.05.016
Natarajan P, O’Donnell CJ. Reducing Cardiovascular Risk Using Genomic Information in the Era of Precision Medicine. Circulation. 2016;133(12):1155-9. doi:10.1161/CIRCULATIONAHA.116.021765
Musunuru K, Kathiresan S. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circ Res. 2016;118(4):579-85. doi:10.1161/CIRCRESAHA.115.306398
Musunuru K, Lettre G, Young T, et al. Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet. 2010;3(3):267-75. doi:10.1161/CIRCGENETICS.109.882696
Kathiresan S. Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J Am Coll Cardiol. 2015;65(15):1562-6. doi:10.1016/j.jacc.2015.02.049
Miao J, Ling AV, Manthena PV, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun. 2015;6:6498. doi:10.1038/ncomms7498
Thormaehlen AS, Schuberth C, Won HH, et al. Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction. PLoS Genet. 2015;11(2):e1004855. doi:10.1371/journal.pgen.1004855
Spracklen CN, Saftlas AF, Triche EW, et al. Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. Am J Hypertens. 2015;28(7):915-23. doi:10.1093/ajh/hpu242
Smith G, Luk K, Schulz CA, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312(17):1764-71. doi:10.1001/jama.2014.13959
Tada H, Won HH, Melander O, Yang J, Peloso GM, Kathiresan S. Multiple associated variants increase the heritability explained for plasma lipids and coronary artery disease. Circ Cardiovasc Genet. 2014;7(5):583-7. doi:10.1161/CIRCGENETICS.113.000420